Evaluation of genetic factors for warfarin dose prediction - Wikidata - awgldk - TriplyDB

Evaluation of genetic factors for warfarin dose prediction

Evaluation of genetic factors for warfarin dose prediction

http://www.wikidata.org/entity/Q35758421

about

CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease.Estimation of the warfarin dose with clinical and pharmacogenetic data.The Wisconsin Network for Health Research (WiNHR): a statewide, collaborative, multi-disciplinary, research group.Implementing genotype-guided antithrombotic therapy.CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.Genetic education and the challenge of genomic medicine: development of core competences to support preparation of health professionals in Europe CYP4F2 genetic variant alters required warfarin dose Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy.Absence of novel CYP4F2 and VKORC1 coding region DNA variants in patients requiring high warfarin doses Warfarin dose requirement in Turkish patients: the influences of patient characteristics and polymorphisms in CYP2C9, VKORC1 and factor VII Practical Consideration of Genotype Imputation: Sample Size, Window Size, Reference Choice, and Untyped Rate.A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics.Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study.Enzyme Polymorphism in Warfarin Dose Management After Pediatric Cardiac Surgery.Genetic polymorphisms of patients on stable warfarin maintenance therapy in a Ghanaian population.The Impact of Genetic and Non-Genetic Factors on Warfarin Dose Prediction in MENA Region: A Systematic Review.The future of warfarin pharmacogenetics in under-represented minority groups.Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose Role of pharmacogenomics in the management of traditional and novel oral anticoagulants Exposure to non-therapeutic INR in a high risk cardiovascular patient: potential hazard reduction with genotype-guided warfarin (Coumadin) dosing Does CALU SNP rs1043550 contribute variability to therapeutic warfarin dosing requirements?VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.Pharmacogenetics of vitamin K antagonists: useful or hype?Potential of a Pharmacogenetic-Guided Algorithm to Predict Optimal Warfarin Dosing in a High-Risk Hispanic Patient: Role of a Novel NQO1*2 Polymorphism.A new nested allele-specific multiplex polymerase chain reaction method for haplotyping of VKORC1 gene to predict warfarin sensitivity.Clinical applications of pharmacogenomics guided warfarin dosing.A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?Current challenges in personalizing warfarin therapy.Theranostics in primary care: pharmacogenomics tests and beyond.

P2860

Q24322624-FCB26B7B-FD2F-4529-9AA3-DDB4422EBF30 Q26823542-3576F207-BAF3-4AD6-8ABF-22CB8881A414 Q27002899-BBAA5BE3-0546-446B-BF33-F72490953E8C Q30558676-4B120B89-3D8F-4CEB-BE55-6015DF218462 Q33410725-930B613F-D1F3-425C-B0DE-F1DED1F8F3CA Q33779464-88E1B144-7D73-4BC2-9675-2915AA51290A Q33990428-367B2FD9-3002-4F75-A484-069DDCC10F32 Q34026257-C98A401E-533D-4718-B0E3-DA01C000FFED Q34061511-7AD5AA7C-AFD7-42A9-9328-0E446E370363 Q34179616-EF79DB01-7112-4D9C-822F-5B7192FDAC75 Q34329539-E5B3E1C1-DCC6-4DB9-893C-ACF96DA3F469 Q34746151-2AD1D57D-14FE-4D38-8B4A-A998E30E6680 Q35092508-9DCDFC27-C721-4E90-A3F8-B3283C2A8F49 Q35652161-262C134C-AA01-4B26-ADCC-11B4EC4391F8 Q35678294-3D620C6A-0F82-431C-A1C4-6A8E7A76435D Q35720540-0CB7DC6C-5D84-47D0-910A-DA976DB1CF70 Q35888757-2C1FD92E-E9DF-4E57-9466-FC94F7A439AB Q35900767-64926B74-0A88-4AB6-B4F6-18D7392B64E3 Q36118277-7AFEF22F-B102-47A0-B711-812BCF402306 Q36219235-D1E6C0FF-C992-4051-9280-31D4A3EB8758 Q36228428-214C7BC9-3E20-4A02-BAEA-6188AFD9EBF5 Q36294461-237D4293-0B63-4AD4-B6D4-61FC6DC74AC0 Q36527206-41169682-2A0F-4C84-961D-88A636537F29 Q36835168-F966C359-90EE-49C0-AD7F-30B6B3EFB3EE Q36835176-EBA60B11-506B-4631-99EB-263AFC1BE770 Q36848449-E38E8CD8-183E-4817-8AE0-B3C34B1BD6D6 Q36921008-2A7B3A7E-D88F-4CC2-A3EB-59280405828E Q36954725-0BD7DDC7-12AA-44DF-9138-490C5F17C9DC Q36982736-8CA68540-C9D0-47A4-BABD-5209394C3D10 Q37160420-D77C9D4F-8C79-4ED8-99E3-D49AEE1F84E3 Q37169126-7BEA6A27-0ADA-4176-9F30-5F1804EA08C5 Q37276490-F8175F29-3F16-4C84-A2AB-33628D5B4EA4 Q37376879-8AC62447-DC65-4A12-8F70-D4134B53C93B Q37461474-56331282-AE00-4468-AB15-F0364E4B2CD5 Q37632365-5B66BA45-ED94-417B-96B6-DEF3472C913D Q37700486-C638A124-92AC-44B2-948C-70CA56DF03C1 Q37807280-A2971301-10AE-4FC5-BA46-1D3D7FEA2342 Q37908891-CC787051-2466-4FB7-A3B2-5683462558FC Q37960511-8C735E38-9326-4A5E-8227-B38D80AE194E Q38068223-38448916-CA48-4BA3-9F78-158398768A50

P2860

Evaluation of genetic factors for warfarin dose prediction

http://www.wikidata.org/entity/Q35758421

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Evaluation of genetic factors for warfarin dose prediction

@ast

Evaluation of genetic factors for warfarin dose prediction

@en

type

label

Evaluation of genetic factors for warfarin dose prediction

@ast

Evaluation of genetic factors for warfarin dose prediction

@en

prefLabel

Evaluation of genetic factors for warfarin dose prediction

@ast

Evaluation of genetic factors for warfarin dose prediction

@en

P1433

Q35758421-92F05600-A094-4A50-A6E7-1B47421DA2A7

P1476

Q35758421-F160CBF3-3D51-4AEA-83E8-4FC76616C9C5

P2093

Q35758421-0D0B9DDE-522E-4D19-B26B-F3FF84DDA5E2

Q35758421-23435482-091D-4695-82AD-07847441283B

Q35758421-4FEF1D39-2563-4823-B266-7F9F179BB06F

Q35758421-541B333E-BE01-43A2-A893-6EB0C3AA9D70

Q35758421-73E049D5-DEF3-4E5C-9373-B5C41286A957

Q35758421-791C22B9-0054-4547-A771-C89374E02522

Q35758421-F3274405-ED49-481C-A3CC-3941CBA61149

Q35758421-FBC9E3E6-FD49-4795-96A0-47C1BA547E71

P2860

Q35758421-02B785A3-7E2B-449C-B6F0-340A9A9F2FC2

Q35758421-15EA0E42-88DC-47CD-9FFB-8C0829006C4B

Q35758421-15ECE0CC-547B-407A-B231-0191D07930FE

Q35758421-1823ED22-EC78-4C73-B3A1-FD28FF78106F

Q35758421-31706443-1B1A-4FE8-B882-C112CD785FA4

Q35758421-3C2B4FB9-2680-4AB4-A1C6-A20650DCDA60

Q35758421-3F5379DE-BCB8-448E-980E-941B59EAB1F1

Q35758421-5343C2DF-F30B-44DE-B202-CB80776F8014

Q35758421-59767D71-353D-466D-AA7E-D91E83560508

Q35758421-5E462482-24F5-4D9A-84D1-EC64DEA06F66

P304

Q35758421-5F71C6CD-3D93-4194-98B7-4536EA5D5435

P31

Q35758421-DDD2343D-FA53-4351-9A73-2762DEE71FA0

P356

Q35758421-982D74D5-4ADB-4A95-B2C5-6D56A2788939

P433

Q35758421-68227C16-31CF-4130-A4CA-78207CB80CBD

P478

Q35758421-91AA89CF-9038-471E-BE83-3210C86430DC

P577

Q35758421-8CBAF2AF-DB4E-410D-85B3-BB2D9F174488

P5875

Q35758421-29900A5E-4D6C-469F-9197-ECCCA56EAE14

P698

Q35758421-F9CF96C9-A283-4F63-94A2-388AB122683E

P932

Q35758421-FB01D0BE-F9C9-4104-B928-E2529C079DD0

P356

P1433

Clinical Medicine and Research

P1476

Evaluation of genetic factors for warfarin dose prediction

@en

P2093

Humberto J Vidaillet

http://www.w3.org/2001/XMLSchema#string

Ingrid Glurich

http://www.w3.org/2001/XMLSchema#string

James K Burmester

http://www.w3.org/2001/XMLSchema#string

John R Schmelzer

http://www.w3.org/2001/XMLSchema#string

Kai Qi Zhang

http://www.w3.org/2001/XMLSchema#string

Michael D Caldwell

http://www.w3.org/2001/XMLSchema#string

Richard L Berg

http://www.w3.org/2001/XMLSchema#string

Steven H Yale

http://www.w3.org/2001/XMLSchema#string

P2860

The morbidity related to atrial fibrillation at a tertiary centre in one year: 9.0% of all strokes are potentially preventable

An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats

A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data

Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing.

Prophylaxis and treatment of deep vein thrombosis in general surgery.

CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis.

Common VKORC1 and GGCX polymorphisms associated with warfarin dose.

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

P304

8-16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3121/CMR.2007.724

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2007-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6371994

http://www.w3.org/2001/XMLSchema#string

P698

17456829

http://www.w3.org/2001/XMLSchema#string

P932

1855340

http://www.w3.org/2001/XMLSchema#string